Dianne Schlachter, MD
Ophthalmic Plastic and Reconstructive Surgery · Detroit, MINPI 1659582773
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,620 of the $52,478 with a category attached, or 86.9%. Amgen accounts for 98.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $20,433 and has fallen 99.2% since, to $158 in 2025.
Across 88 payments — averaging $596.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$52K
- Alcon$162
- Genentech USA, Inc.$145
- Sun Pharmaceutical Industries Inc.$138
- Stryker$65
- AbbVie$33
- plus $24 from 2 others
What the payments were for
- Consulting fees$8952%
- Speaking & faculty fees$45,62087%
- Travel & lodging$2,8645%
- Food & beverage$3,0996%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 79 | $51,911 |
| Alcon | 1 | $162 |
| Genentech USA, Inc. | 1 | $145 |
| Sun Pharmaceutical Industries Inc. | 2 | $138 |
| Stryker | 1 | $65 |
| AbbVie | 2 | $33 |
| Biotissue Holdings Inc. | 1 | $14 |
| Amniox Medical, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Michiganto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 43 | $574 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 17 | $227 |
| ValacyclovirValacyclovir Hcl | 17 | $107 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Detroit
- Evan BlackDetroit$791
- Alon KahanaLivonia$181K
- Jasmina BajricGrand Rapids$57K
- Shannon JosephTroy$9K
- Adam HassanGrand Rapids$2K
- Zachary PearceClinton Twp$1K
- Michael BoyleGrand Rapids$1K
- Shravani MikkilineniSouthfield$1K
- Tiffany KentGrand Rapids$624
- Geoffrey GladstoneSouthfield$429
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.